Muscarinic receptors and salivary secretion

Abstract

INVITED EDITORIALMuscarinic receptors and salivary secretionGordon B. ProctorGordon B. ProctorPublished Online:01 Apr 2006https://doi.org/10.1152/japplphysiol.01546.2005MoreSectionsPDF (53 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInEmailWeChat The release of acetylcholine from parasympathetic nerves and its interaction with muscarinic acetylcholine receptors (mAChRs) regulates many fundamental functions in the periphery (smooth muscle contraction, glandular secretion, modulation of cardiac output) and central nervous system (motor control, thermoregulation, memory). Five subtypes of mAChR, M1–M5, have been designated on the basis of cDNA cloning, and the interactions of agonists and antagonists with these receptors, along with their intracellular coupling through different G proteins, continue to be characterized (2). Given the range of important functions regulated by mAChRs, they are frequently therapeutic targets in treatment of a number of pathologies. Muscarinic agonists continue to be developed for use in treating Alzheimer's disease, nociceptive pain, schizophrenia, and xerostomia, whereas muscarinic antagonists have been developed to treat Parkinson's disease, urinary incontinence, irritable bowel syndrome, gastric ulceration, and chronic obstructive pulmonary disease (4). Progress in therapeutics has been hindered by a lack of resolution of the roles that the different mAChRs play in physiology. Muscarinic agonists and antagonists currently used therapeutically lack the necessary selectivity to prevent unwanted side effects. A frequent side effect of the use of muscarinic antagonists is inhibition of salivary secretion, leading to xerostomia or chronic dry mouth (4).Salivary gland secretion is a reflex, the efferent arm of which is mediated by both branches of the autonomic nervous system. Stimuli mediated by sympathetic secretomotor nerves modify the protein composition of saliva and evoke a modest fluid secretory response. However, salivary secretion is almost completely abolished by atropine, and it is clear that release of acetylcholine from parasympathetic nerves plays the main role in evoking fluid secretion, acting via mAChRs on salivary secretory cells. The three pairs of major salivary glands (parotid, submandibular, and sublingual) differ in the details of how autonomic control is exerted and in the types of saliva secreted, both within and between species. However, despite this variety, there has been a tendency to base most of our understanding of salivary secretion on the most frequently employed animal model, the rat parotid gland (1). There has been a widespread acceptance, based on studies of the rat parotid gland, that salivary secretion is mediated entirely by M3 receptors.To develop more selective muscarinic antagonists without the xerostomic side effect, we need to gain an understanding of how different muscarinic receptor subtypes are involved in the physiological control of salivary secretion. The paper by Tobin and colleagues, including the late Tony Edwards, in the current issue of the Journal of Applied Physiology, examines the effects of muscarinic antagonists on electrical stimulation of parasympathetic (chorda lingual) nerve-mediated secretion of saliva by the ovine submandibular gland (13). Antisera directed against the different mAChRs were also used immunocytochemically and on tissue homogenates to provide further evidence for the presence of particular subtypes. The results indicate a role for M1 receptors in addition to M3 receptors in mediating salivary fluid secretion and a possible role for M4 receptors in regulating salivary protein secretion. Previous studies by Tobin and coworkers (11, 12) and others (3) indicate that secretion by the rabbit and rat submandibular and rat sublingual salivary glands is also partially mediated by M1 and other non-M3 receptors.Further progress in resolving the contributions made by different mAChRs to the control of salivary secretion has followed from the generation of mutant mice with single or double knockouts of different mAChRs (e.g., Refs. 5, 10). These studies indicate that both M1 and M3 receptors make a contribution to the secretion of whole mouth saliva (the combined secretion of all of the salivary glands) evoked by pilocarpine and other muscarinic agonists. The M1 receptor appears to make more of a contribution at higher doses of pilocarpine, whereas the M3 receptor appears to be important in mediating secretion in response to lower doses of agonist. In the present study by Tobin et al. (13), nerve stimulation can be regarded as a “more physiological” form of stimulation, and the contribution of the M1 receptor appeared to be greater at lower frequencies of stimulation. Interestingly, there was reduced fluid but not protein secretion in response to stimulation in the presence of M1 receptor blocker. This might suggest a difference between the M1 and M3 receptors in intracellular coupling of stimulation to secretion, although Culp's group (8) found no evidence of different G protein coupling for these receptors in the rat sublingual gland. Studies of carbachol-induced calcium signaling in mAChR knockout mice suggest that, unlike M3 receptors, M1 receptors are not ubiquitously expressed on submandibular acinar cells (10). Similar studies on the parotid gland do not appear to have been undertaken. Given the earlier demonstration of a relatively greater contribution of M3 receptors to parotid gland secretion, it may be that the saliva secreted in M3 knockout mice is predominantly from submandibular and sublingual glands. Radioligand binding studies on human submandibular and labial minor salivary glands indicate the presence of both M1 and M3 receptors (7, 9).It is generally accepted that the parotid glands in humans make a greater contribution to the whole mouth saliva secreted in response to overt stimulation during the tasting and chewing of food. The nonparotid glands make a greater contribution to the resting or “background” whole mouth saliva that coats the oral surfaces for most of the day and night between episodes of stronger stimulation. We can speculate that the development of more selective M3 receptor antagonists might affect parotid function but allow sufficient function of other salivary glands to reduce the most severe dry mouth side effects. Although the expression of other mAChRs may increase in pathology, leading to a more complex picture (6), more selective M3 antagonists may have therapeutic applications in the treatment of urinary incontinence and other pathologies.REFERENCES1 Baum BJ and Wellner RB. Receptors in salivary glands. In: Neural Mechanisms of Salivary Secretion. Frontiers in Oral Biology, edited by Garrett JR, Ekström J, and Anderson LC. Basel: Karger, 1999, vol. 11, chapt. 3, p. 44–58.Crossref | Google Scholar2 Caulfield MP and Birdsall NJM. International union of pharmacology. XVII classification of muscarinic acetylcholine receptors. Pharmacol Rev 50: 279–290, 1998.PubMed | ISI | Google Scholar3 Culp DJ, Luo W, Richardson LA, Watson GE, and Latchney LR. Both M1 and M3 receptors regulate exocrine secretion by mucous acini. Am J Physiol Cell Physiol 271: C1963–C1972, 1996.Link | ISI | Google Scholar4 Eglen RM, Choppin A, Dillon MP, and Hegde S. Muscarinic receptor ligands and their therapeutic potential. Curr Opin Chem Biol 3: 426–432, 1999.Crossref | ISI | Google Scholar5 Gautam D, Heard TS, Cui Y, Miller G, Bloodworth L, and Wess J. Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice. Mol Pharmacol 66: 260–267, 2004.Crossref | PubMed | ISI | Google Scholar6 Giglio D, Ryberg AT, To K, Delbro DS, and Tobin G. Altered muscarinic receptor subtype expression and functional responses in cyclophosphamide induced cystitis in rats. Auton Neurosci 122: 9–20, 2005.Crossref | PubMed | ISI | Google Scholar7 Giraldo E, Martos F, Gomez A, Garcia A, Vigano MA, Ladinsky H, and Sanchez de La Cuesta F. Characterization of muscarinic receptor subtypes in human tissues. Life Sci 43: 1507–1515, 1988.Crossref | PubMed | ISI | Google Scholar8 Luo W, Latchney LR, and Culp DJ. G protein coupling to M1 and M3 muscarinic receptors in sublingual glands. Am J Physiol Cell Physiol 280: C884–C896, 2001.Link | ISI | Google Scholar9 Mei L, Roeske WR, Izutsu KT, and Yamamura HI. Characterization of muscarinic acetylcholine receptors in human labial salivary glands. Eur J Pharmacol 176: 367–370, 1990.Crossref | PubMed | ISI | Google Scholar10 Nakamura T, Matsui M, Uchida K, Futatsugi A, Kusakawa S, Matsumoto N, Nakamura K, Manabe T, Taketo MM, and Mikoshiba K. M3 muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice. J Physiol 558: 561–575, 2004.Crossref | PubMed | ISI | Google Scholar11 Tobin G. Muscarinic receptor subtypes in the submandibular gland and the urinary bladder of the rabbit: in vivo and in vitro functional comparisons of receptor antagonists. J Auton Pharmacol 15: 451–463, 1995.Crossref | Google Scholar12 Tobin G, Giglio D, and Gotrick B. Studies of muscarinic receptor subtypes in salivary gland function in anaesthetized rats. Auton Neurosci 100: 1–9, 2002.Crossref | PubMed | ISI | Google Scholar13 Tobin G, Ryberg AT, Gentle S, and Edwards AV. Distribution and function of muscarinic receptor subtypes in the ovine submandibular gland. J Appl Physiol 100: 1215–1223, 2006.Link | ISI | Google Scholar Download PDF Previous Back to Top Next FiguresReferencesRelatedInformationCited ByTuft Cells Are Present in Submandibular Glands Across Species21 August 2022 | Journal of Histochemistry & Cytochemistry, Vol. 39Beyond Digestion: Can Animals Shape the Landscape According to Their Species–Specific Salivary Secretions?28 August 2021 | Agriculture, Vol. 11, No. 9In Vivo Monitoring of Acetylcholine Release from Nerve Endings in Salivary Gland21 April 2021 | Biology, Vol. 10, No. 5Disturbed Gastrointestinal Contractility in a Polycystic Ovary Syndrome Rat Model6 August 2020 | Digestive Diseases and Sciences, Vol. 65, No. 10Allosteric modulation of G protein‐coupled receptors by amiloride and its derivatives. Perspectives for drug discovery?8 September 2019 | Medicinal Research Reviews, Vol. 40, No. 2Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M 3 Receptor Antagonist/ β2 -Adrenoceptor Agonist Molecule with Long-Lasting Effects and Favorable Safety Profile13 May 2019 | Journal of Pharmacology and Experimental Therapeutics, Vol. 370, No. 1Evaluating the effect of three newly approved overactive bladder syndrome treating agents on parotid and submandibular salivary glands: Modulation of CXCL10 expressionActa Histochemica, Vol. 120, No. 3Epithelial disruptions, but not immune cell invasion, induced secretory dysfunction following innate immune activation in a novel model of acute salivary gland injury18 December 2017 | Journal of Oral Pathology & Medicine, Vol. 47, No. 2Histological and immunohistochemical findings of the action of botulinum toxin in salivary gland: systematic review5 September 2016 | Brazilian Journal of Biology, Vol. 77, No. 2Current trends in salivary gland tight junctions10 March 2016 | Tissue Barriers, Vol. 4, No. 3Calcium signalling in salivary gland physiology and dysfunction15 December 2015 | The Journal of Physiology, Vol. 594, No. 11Morphological changes in the salivary acini after in vivo cholinergic stimulation25 March 2015 | Neurourology and Urodynamics, Vol. 35, No. 5Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder25 March 2014 | International Journal of Clinical Practice, Vol. 68, No. 8Botulinum toxin A inhibits salivary secretion of rabbit submandibular gland25 October 2013 | International Journal of Oral Science, Vol. 5, No. 4Inhaled muscarinic antagonists for respiratory diseases: a review of patents and current developments (2006 – 2010)25 June 2011 | Expert Opinion on Therapeutic Patents, Vol. 21, No. 10Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonistsBioorganic & Medicinal Chemistry Letters, Vol. 21, No. 11Altered plasticity of the parasympathetic innervation in the recovering rat submandibular gland following extensive atrophy15 January 2009 | Experimental Physiology, Vol. 94, No. 2Central muscarinic receptor subtypes involved in pilocarpine-induced salivation, hypertension and water intake29 January 2009 | British Journal of Pharmacology, Vol. 155, No. 8Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit modelEuropean Journal of Pharmacology, Vol. 572, No. 2-3Regulation of salivary gland function by autonomic nervesAutonomic Neuroscience, Vol. 133, No. 1Secretion and Fluid Transport Mechanisms in the Mammary Gland: Comparisons with the Exocrine Pancreas and the Salivary Gland30 November 2006 | Journal of Mammary Gland Biology and Neoplasia, Vol. 11, No. 3-4 More from this issue > Volume 100Issue 4April 2006Pages 1103-1104 Copyright & PermissionsCopyright © 2006 the American Physiological Societyhttps://doi.org/10.1152/japplphysiol.01546.2005PubMed16540706History Published online 1 April 2006 Published in print 1 April 2006 Metrics